Resmed Inc. (NYSE: RMD) closed the day trading at $184.36 down -2.62% from the previous closing price of $189.32. In other words, the price has decreased by -$4.96 from its previous closing price. On the day, 984516 shares were traded. RMD stock price reached its highest trading level at $188.29 during the session, while it also had its lowest trading level at $182.29.
Ratios:
For a better understanding of RMD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 128.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.18. For the most recent quarter (mrq), Quick Ratio is recorded 1.89 and its Current Ratio is at 3.11. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.30.
On October 27, 2023, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight and also lowered its target price recommendation from $180 to $169.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on October 12, 2023, whereas the target price for the stock was revised from $273 to $202.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Rider Michael J sold 81 shares for $180.00 per share. The transaction valued at 14,580 led to the insider holds 6,607 shares of the business.
Rider Michael J sold 200 shares of RMD for $34,650 on Mar 01 ’24. The Global General Counsel now owns 6,688 shares after completing the transaction at $173.25 per share. On Feb 22 ’24, another insider, FARRELL PETER C, who serves as the Director of the company, sold 10,935 shares for $182.66 each. As a result, the insider received 1,997,434 and left with 157,404 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RMD now has a Market Capitalization of 27.12B and an Enterprise Value of 28.30B. As of this moment, Resmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 30.54, and their Forward P/E ratio for the next fiscal year is 22.37. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.02 while its Price-to-Book (P/B) ratio in mrq is 6.05. Its current Enterprise Value per Revenue stands at 6.28 whereas that against EBITDA is 19.79.
Stock Price History:
Over the past 52 weeks, RMD has reached a high of $243.52, while it has fallen to a 52-week low of $132.24. The 50-Day Moving Average of the stock is 186.80, while the 200-Day Moving Average is calculated to be 173.47.
Shares Statistics:
Over the past 3-months, RMD traded about 995.19K shares per day on average, while over the past 10 days, RMD traded about 1.12M shares per day. A total of 147.06M shares are outstanding, with a floating share count of 145.92M. Insiders hold about 0.80% of the company’s shares, while institutions hold 56.52% stake in the company. Shares short for RMD as of Mar 15, 2024 were 7.66M with a Short Ratio of 7.70, compared to 6.58M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.21% and a Short% of Float of 5.94%.
Dividends & Splits
RMD’s forward annual dividend rate is 1.88, up from 1.84 a year ago. Against a Trailing Annual Dividend Yield of 0.97%, it implies a Forward Annual Dividend Yield of 1.04%. The stock’s 5-year Average Dividend Yield is 0.87. The current Payout Ratio is 28.91% for RMD, which recently paid a dividend on Mar 14, 2024 with an ex-dividend date of Feb 07, 2024. Stock splits for the company last occurred on Aug 31, 2010 when the company split stock in a 2:1 ratio.
Earnings Estimates
Current recommendations for the stock of the company come from 9 analysts. On average, analysts expect EPS of $1.9 for the current quarter, with a high estimate of $1.98 and a low estimate of $1.81, while EPS last year was $1.68. The consensus estimate for the next quarter is $1.96, with high estimates of $2.09 and low estimates of $1.86.
Analysts are recommending an EPS of between $8.26 and $7.24 for the fiscal current year, implying an average EPS of $7.45. EPS for the following year is $8.13, with 12 analysts recommending between $8.92 and $7.33.
Revenue Estimates
A total of 17 analysts have provided revenue estimates for RMD’s current fiscal year. The highest revenue estimate was $4.7B, while the lowest revenue estimate was $4.59B, resulting in an average revenue estimate of $4.63B. In the same quarter a year ago, actual revenue was $4.22B, up 9.70% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $4.93B in the next fiscal year. The high estimate is $5.05B and the low estimate is $4.42B. The average revenue growth estimate for next year is up 6.30% from the average revenue estimate for this year.
